Form 4: Precision BioSciences Executive J. Jefferson Smith Reports Stock Transactions
SEC Form 4 Filing
J. Jefferson Smith, Chief Research Officer at Precision BioSciences, reports acquisition and disposal of company stock related to RSU vesting and tax obligations.
Summary
- J. Jefferson Smith, Chief Research Officer of Precision BioSciences, filed a Form 4 detailing changes in beneficial ownership.
- On February 29, 2024, Smith acquired 1,006 shares of common stock at $12.42 per share.
- On May 1, 2024, 519 shares were acquired through the vesting of Restricted Stock Units (RSUs).
- On May 2, 2024, 154 shares were sold at an average price of $10.32 to cover tax withholding obligations related to the RSU vesting.
- Following these transactions, Smith directly owns 67,613 shares and indirectly owns 7,931 shares through a Charitable Remainder Unitrust.
- The reported amounts of securities have been adjusted to reflect a 1-for-30 reverse stock split that occurred on February 13, 2024.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and related to compensation and tax obligations. There's no indication of unusual or concerning activity.
Positives
- The acquisition of shares through RSU vesting indicates a continued alignment of the executive's interests with the company's performance.
Negatives
- The sale of shares, even if for tax obligations, could be perceived negatively by some investors, although the explanation clarifies the reason.
Risks
- Fluctuations in the stock price could impact the value of the executive's holdings and potentially influence future decisions regarding stock transactions.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
- The transactions reported are typical for executives receiving stock-based compensation, such as RSUs, and selling shares to cover tax obligations.
- Similar filings can be observed for executives at comparable biotechnology companies like CRISPR Therapeutics or Editas Medicine.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
- Transparency through Form 4 filings helps maintain investor confidence.
Key Dates
| Date | Description |
|---|---|
| 2022-03-03 | Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023. |
| 2023-03-03 | First vesting date of RSUs granted on March 3, 2022. |
| 2024-02-13 | Precision BioSciences effected a 1-for-30 reverse stock split. |
| 2024-02-29 | Acquisition of 1,006 shares of common stock at $12.42 per share. |
| 2024-05-01 | Acquisition of 519 shares through RSU vesting. |
| 2024-05-02 | Sale of 154 shares at an average price of $10.32 to cover tax obligations. |
| 2024-05-03 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.